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vi Abstracts 
Patient Select ion 
We need to be aware that patients assessed by a specialist will be different o those referred by a general 
practitioner and even more so to the highly motivated volunteer OA sufferer who was recruited for the trial 
after reading a newspaper advertisement. 
Disease Subsets 
It is now well recognised that OA of different joints has varying disease onset and progression, combining 
patients in global OA trials may dilute important subset effects. However, the move in recent intra-articular 
therapy trials to find the homogenous nilateral medial tibio-femoral OA in select age, sex and racial groups 
leads to many potential recipients being excluded and makes trial recruitment at a single site impractical. 
Can we use patients with bilateral disease as their own controls? Can we expect patients with bilateral 
disease to accurately assess outcomes? Can we mount large multi-centre trails that include suficient numbers 
in multiple disease subsets? 
Outcome Measures 
Are the current measures that have been well validated for the advanced OA patient undergoing joint 
replacement surgery suitable for the young active patient with early OA whose main aim is to get back to 
running or competition tennis? 
Trial Sett ing and Conduct 
How much influence does the special research clinic and the attentive metrologist have on the patient 
responses? Could or should we mimic "usual patient care"? 
Symptom control 
To evaluate disease modification patients will need to be observed over periods of at least two years. Are 
we expecting too much of the new therapies that they should control symptoms in the immediate and 
long-term? Will combination therapy be required? 
Drop-outs 
Analysis should be by intention-to-treat as placebo-controlled long-term studies for OA to date have had a 
significant differential in drop-out rates between active and placebo arms. Should we encourage patients to 
maintain trail protocol and avoid all other therapies or are we just increasing the chance of finding no 
difference? Drop-out rates should be an important outcome measure. 
Placebo Response 
How can we see a treatment effect when the placebo group report up to 60% treatment satifaction and 
improvement in pain and function? 
Osteoarthritis is a common and disabling condition and the implications of a disease modifying therapy are 
substantial. Once the challenges of radiological biochemical and histopathological assessment of disease 
progression have been met then large multi-centre trials with randomisation within subsets of OA must be 
undertaken. 
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Objective 
Pentosan polysulphate (PPS) (Cartrophen) is a new anti-osteoarthritis drug which from laboratory and 
animal studies [1] offers potential for disease modification in osteoarthritis (OA). The present study was 
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undertaken to determine if intra-articular (i.a.) administration of PPS to patients with gonoarthrit is was 
clinically efficacious and capable of improving biochemical markers of OA disease activity in their synovial 
fluids (SF). 
Methods  
Fifty patients were enrolled in the study but only 31 (16 placebo and 15 PPS) have completed the 
protocol to date. Rigorous entry requirements elected only patients with unilateral OA or clearly 
separable bilateral joint disease. The target joints had to have Kellgren OA grades of 2-3. patients 
pain on walking was required to exceed 20 mm on a visual analogue scale (VAS) and none were to 
have received other i.a. therapies or knee trauma previously. Following a two week NSAID wash-out 
period, patients were assessed at baseline using a number of clinical criteria including: time to walk 
50 ft (t50), visual analogue scale (VAS) of maximum pain (VAS max) pain during previous 48 h and month, 
WOMAC visual analogue scores for pain stiffness and functional deficits [2], global assessment of 
treatment, range of motion, crepitus, joint diameter, effusion. Synovial fluid was also collected for analysis. 
Patients were then assigned randomly to a course of 4 weekly i.a. injections of either lml Ringer's 
solution (placebo) of lml PPS (50 mg) allocated under "double-blinded conditions". SF was collected 
and patients clinical status determined at the time of each i.a. injection (weeks 0, 1 2, 3) and assessed 
clinically on weeks 4, 5, 9, 12, 16, 21 and 26 thereafter. Centrifuged SF was analysed for concentration 
of osteocalcin, metalloproteinase-3 (MMP3), tissue inhibitor of metalloproteinase (TIMP) using 
commercially available kits and nitric oxide (NO) free radical (as nitrite ion) using the Greiss reagent [3]. 
Weekly pain indices (times, VAS) and functional scores (VAS) were expressed as a change from baseline 
(week 0) for each patient. Dropouts were analysed by intention to treat. Statistical comparison for 
change from baseline for each patient and between placebo and PPS groups were made using the paired 
Student's test (p _< 0.05 = significant). 
Resu l ts  
In the placebo-treated group, clinical improvement from baseline was seen for the t50 test on weeks 16 
(p = 0.04) and 26 (p = 0.02) and weeks 9-21 for some WOMAC indices. However, in all cases the PPS treated 
group showed stronger statistical significance than the placebo group for the same indices. In addition, 
statistical differences between the PPS-treated and placebo groups were observed for stiffness (weeks 5, 6, 
21, p < 0.05), walking on the flat (week 9, p < 0.03), getting out of car (week 9, p < 0.05), t50 (weeks 4, 5, 9, 
12, 16, 21, p < 0.05) pain in the previous 48h (weeks 9, 12, p < 0.02) and previous month (weeks 4, 5, 9, 12, 16, 
p = 0.01-0.04). Analysis of SF for MMP3 and TIMP failed to show any correlations with treatments. However, 
in the PPS-treated groups osteocalcin levels diminished relative to baseline on weeks 1 (p = 0.03), week 2 
(p = 0.02) and 3 (p = 0.02) whereas the placebo group levels remained constant and were higher than PPS on 
week 2 (p = 0.05)and 3 (p = 0.06). NO levels in SF were found to be lower in the PPS group relative to placebo 
on week 3 (p = 0.001). 
Conc lus ions  
Even with the limited number of patients so far evaluated and the high clinical response found for the 
placebo-treated patients, PPS exhibited significant improvement in pain and mobility indices for up to 2 
months after completing the treatment protocol, Significantly, osteocalcin (a marker of osteoclast activity 
and bone remodelling [4]) and NO levels in SF of PPS patients were lower than in the placebo group 
suggesting that the clinical benefits of the drug could be"related to pharmacological modification of the 
underlying pathology responsible for symptoms. 
References  
[1] Ghosh P, Smith M and Wells C: In: Second Line Agents in the treatment of Rheumatic Diseases. (Eds) 
Dixon JS, Furst DE, Marcel Dekker Inc, 1992, 363-427. [2] Bellamy N: WOMAC osteoarthritis ndex-A users 
guide, 1995. [3] Drapier JC and Hibbs (Jr) JB, (1988) J. Immununol: 140: 2829-2838. [4] Sharif M, George 
E and Dieppe PA: Arthritis Rheum, 38: 78-81, 1995. 
